Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Residual Neuromuscular Blockade
Interventions
Standardized NMBD Management
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Riverside, California • San Francisco, California • Sanford, Florida + 8 more
Conditions
Acute Myocardial Infarction, Acute Coronary Syndrome
Interventions
Cardiac Troponin Testing
Diagnostic Test
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Advanced Solid Tumor
Interventions
SGN1
Drug
Lead sponsor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more
Conditions
Neuroectodermal Tumors, Primitive, Liver Neoplasms, Osteosarcoma, Other Childhood Cancers Using Cisplatin-based Regimens
Interventions
N-Acetylcysteine
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Obesity and Obesity-related Medical Conditions, Weight Loss
Interventions
No Intervention: Observational Cohort
Other
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Evanston, Illinois • Bellaire, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 Inhibitor (DPP-4), Glucagon-Like Peptide-1 Agonist (GLP-1), Thiazolidinedione (TZD), Sulfonylureas, Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
25,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Trevose, Pennsylvania
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Comparing Facial Aging Between Identical Twins With 3D Imaging

NCT07760532
Conditions
Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
Interventions
GLP-1 Receptor Agonists
Drug
Lead sponsor
Ponsky Facial Aesthetics And Plastic Surgery, Llc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Beachwood, Ohio
Conditions
Surgery, Anaesthesia, Ventilator-Induced Lung Injury, Lung Injury, Pneumonia, Pneumothorax, Respiratory Distress Syndrome, Adult, Respiratory Insufficiency
Interventions
Not listed
Lead sponsor
European Society of Anaesthesiology
Other
Eligibility
18 Years and older
Enrollment
10,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota
Enrolling by invitation No phase listed Observational

Federated Learning for Point-of-Care Cardiac Ultrasound

NCT07800962
Conditions
Ventricular Dysfunction, Left, Ventricular Function, Left, Echocardiography, Ultrasonography, Point-of-Care Systems, Heart Function Tests, Stroke Volume, Federated Learning, Machine Learning, Artificial Intelligence (AI), Deep Learning, Neural Networks, Computer, Image Interpretation, Computer-Assisted, Diagnosis, Computer-Assisted, Sensitivity and Specificity, ROC Curve
Interventions
Focused Cardiac Point-of-Care Ultrasonography, FL-POCUS Federated Machine-Learning Analysis System
Diagnostic Test · Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hypogonadism, Hypergonadism, Precocious Puberty, Late Puberty, Amenorrhea
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
8 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Conditions
Chronic Pain, Ketamine
Interventions
Ketamine (Ketalar)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Stanford, California
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Conditions
Graves Disease, Hyperthyroidism/Thyrotoxicosis
Interventions
Heart rate-based AI software for detecting thyrotoxicosis
Device
Lead sponsor
THYROSCOPE INC.
Industry
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Interventions
Not listed
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
148
States / cities
Homewood, Alabama • Anchorage, Alaska • Phoenix, Arizona + 132 more
Conditions
Liver Transplant
Interventions
Everolimus, Tacrolimus (continued reduction), Tacrolimus (maintain 50% reduction)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 9 more
Completed Phase 4 Interventional Results available

QL Block With Exparel in Colectomy

NCT03827291
Conditions
Laparotomy, Colectomy
Interventions
Exparel, Thoracic epidural analgesia
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Endoscopic Eradication Therapy
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more
Conditions
Type1 Diabetes
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Conditions
Infant, Very Low Birth Weight
Interventions
Observational - no intervention
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 3 Days
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Houston, Texas
Conditions
Sepsis, Necrotising Enterocolitis Neonatal
Interventions
No Intervention: Observational Cohort
Other
Lead sponsor
University of Virginia
Other
Eligibility
Not listed
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
HIV
Interventions
rilpivirine/cabotegravir
Drug
Lead sponsor
Whitman-Walker Institute
Government
Eligibility
18 Years and older
Enrollment
180 participants
Timeline
2023 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
17,847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey